APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hemoglobinopathy Testing Services

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Hemoglobinopathy Testing Services Market Outlook and Growth Opportunities 2026

22 December 2025194 pages

Choose your research edition.

Industry ResearchHemoglobinopathy Testing Services Industry Research Report 2026116 pages · $2,950 USDIndustry Growth & TrendsGlobal Hemoglobinopathy Testing Services Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Hemoglobinopathy Testing Services Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hemoglobinopathy Testing Services Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Hemoglobinopathy Testing Services Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Hemoglobinopathy Testing Services market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Hemoglobinopathy Testing Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Hemoglobinopathy Testing Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Hemoglobinopathy Testing Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Hemoglobinopathy Testing Services market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Hemoglobinopathy Testing Services market include Novartis, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca, HemaQuest Pharmaceuticals, Emmaus Medical, Celgene Corporation, Bluebird Bio and Acceleron Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Hemoglobinopathy Testing Services market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hemoglobinopathy Testing Services and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hemoglobinopathy Testing Services revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Hemoglobinopathy Testing Services market.

Hemoglobinopathy Testing Services Segment by Company

Novartis

Eli Lilly and Company

Bristol-Myers Squibb

AstraZeneca

HemaQuest Pharmaceuticals

Emmaus Medical

Celgene Corporation

Bluebird Bio

Acceleron Pharma

Hemoglobinopathy Testing Services Segment by Type

Hydroxyurea

Zynteglo

Luspatercept

Glutamine

Others

Hemoglobinopathy Testing Services Segment by Application

Sickle Cell Diseases

Thalassemia

Other

Hemoglobinopathy Testing Services Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Hemoglobinopathy Testing Services status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Hemoglobinopathy Testing Services key companies, revenue, market share, and recent developments.

3. To split the Hemoglobinopathy Testing Services breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Hemoglobinopathy Testing Services market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hemoglobinopathy Testing Services significant trends, drivers, influence factors in global and regions.

6. To analyze Hemoglobinopathy Testing Services competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hemoglobinopathy Testing Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hemoglobinopathy Testing Services and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hemoglobinopathy Testing Services.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hemoglobinopathy Testing Services industry.

Chapter 3: Detailed analysis of Hemoglobinopathy Testing Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Hemoglobinopathy Testing Services in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Hemoglobinopathy Testing Services in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hemoglobinopathy Testing Services Industry Trends Table 2. Hemoglobinopathy Testing Services Industry Drivers Table 3. Hemoglobinopathy Testing Services Industry Opportunities and Challenges Table 4. Hemoglobinopathy Testing Services Industry Restraints Table 5. Global Hemoglobinopathy Testing Services Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hemoglobinopathy Testing Services Revenue Share by Company (2021-2026) Table 7. Global Hemoglobinopathy Testing Services Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Hemoglobinopathy Testing Services Key Company Manufacturing Base & Headquarters Table 9. Global Hemoglobinopathy Testing Services Company, Product Type & Application Table 10. Global Hemoglobinopathy Testing Services Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Hemoglobinopathy Testing Services by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Hydroxyurea Table 15. Significant Companies of Zynteglo Table 16. Significant Companies of Luspatercept Table 17. Significant Companies of Glutamine Table 18. Significant Companies of Others Table 19. Global Hemoglobinopathy Testing Services Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Hemoglobinopathy Testing Services Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Hemoglobinopathy Testing Services Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Hemoglobinopathy Testing Services Sales Value Share by Type (2021-2026) Table 23. Global Hemoglobinopathy Testing Services Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Sickle Cell Diseases Table 25. Significant Companies of Thalassemia Table 26. Significant Companies of Other Table 27. Global Hemoglobinopathy Testing Services Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global Hemoglobinopathy Testing Services Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global Hemoglobinopathy Testing Services Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global Hemoglobinopathy Testing Services Sales Value Share by Application (2021-2026) Table 31. Global Hemoglobinopathy Testing Services Sales Value Share by Application (2027-2032) Table 32. Global Hemoglobinopathy Testing Services Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global Hemoglobinopathy Testing Services Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global Hemoglobinopathy Testing Services Sales Value Share by Region (2021-2026) Table 35. Global Hemoglobinopathy Testing Services Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global Hemoglobinopathy Testing Services Sales Value Share by Region (2027-2032) Table 37. Global Hemoglobinopathy Testing Services Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Hemoglobinopathy Testing Services Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global Hemoglobinopathy Testing Services Sales Value Market Share by Country (2021-2026) Table 40. Global Hemoglobinopathy Testing Services Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global Hemoglobinopathy Testing Services Sales Value Market Share by Country (2027-2032) Table 42. Novartis Company Information Table 43. Novartis Business Overview Table 44. Novartis Hemoglobinopathy Testing Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Novartis Hemoglobinopathy Testing Services Product Portfolio Table 46. Novartis Recent Development Table 47. Eli Lilly and Company Company Information Table 48. Eli Lilly and Company Business Overview Table 49. Eli Lilly and Company Hemoglobinopathy Testing Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Eli Lilly and Company Hemoglobinopathy Testing Services Product Portfolio Table 51. Eli Lilly and Company Recent Development Table 52. Bristol-Myers Squibb Company Information Table 53. Bristol-Myers Squibb Business Overview Table 54. Bristol-Myers Squibb Hemoglobinopathy Testing Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. Bristol-Myers Squibb Hemoglobinopathy Testing Services Product Portfolio Table 56. Bristol-Myers Squibb Recent Development Table 57. AstraZeneca Company Information Table 58. AstraZeneca Business Overview Table 59. AstraZeneca Hemoglobinopathy Testing Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. AstraZeneca Hemoglobinopathy Testing Services Product Portfolio Table 61. AstraZeneca Recent Development Table 62. HemaQuest Pharmaceuticals Company Information Table 63. HemaQuest Pharmaceuticals Business Overview Table 64. HemaQuest Pharmaceuticals Hemoglobinopathy Testing Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. HemaQuest Pharmaceuticals Hemoglobinopathy Testing Services Product Portfolio Table 66. HemaQuest Pharmaceuticals Recent Development Table 67. Emmaus Medical Company Information Table 68. Emmaus Medical Business Overview Table 69. Emmaus Medical Hemoglobinopathy Testing Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Emmaus Medical Hemoglobinopathy Testing Services Product Portfolio Table 71. Emmaus Medical Recent Development Table 72. Celgene Corporation Company Information Table 73. Celgene Corporation Business Overview Table 74. Celgene Corporation Hemoglobinopathy Testing Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Celgene Corporation Hemoglobinopathy Testing Services Product Portfolio Table 76. Celgene Corporation Recent Development Table 77. Bluebird Bio Company Information Table 78. Bluebird Bio Business Overview Table 79. Bluebird Bio Hemoglobinopathy Testing Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Bluebird Bio Hemoglobinopathy Testing Services Product Portfolio Table 81. Bluebird Bio Recent Development Table 82. Acceleron Pharma Company Information Table 83. Acceleron Pharma Business Overview Table 84. Acceleron Pharma Hemoglobinopathy Testing Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. Acceleron Pharma Hemoglobinopathy Testing Services Product Portfolio Table 86. Acceleron Pharma Recent Development Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. Hemoglobinopathy Testing Services Product Image Figure 2. Global Hemoglobinopathy Testing Services Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hemoglobinopathy Testing Services Market Size (2021-2032) & (US$ Million) Figure 4. Global Hemoglobinopathy Testing Services Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Hydroxyurea Image Figure 8. Zynteglo Image Figure 9. Luspatercept Image Figure 10. Glutamine Image Figure 11. Others Image Figure 12. Global Hemoglobinopathy Testing Services Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Hemoglobinopathy Testing Services Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Hemoglobinopathy Testing Services Sales Value Share by Type (2021-2032) Figure 15. Sickle Cell Diseases Image Figure 16. Thalassemia Image Figure 17. Other Image Figure 18. Global Hemoglobinopathy Testing Services Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global Hemoglobinopathy Testing Services Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global Hemoglobinopathy Testing Services Sales Value Share by Application (2021-2032) Figure 21. Global Hemoglobinopathy Testing Services Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global Hemoglobinopathy Testing Services Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America Hemoglobinopathy Testing Services Sales Value (2021-2032) & (US$ Million) Figure 24. North America Hemoglobinopathy Testing Services Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe Hemoglobinopathy Testing Services Sales Value (2021-2032) & (US$ Million) Figure 26. Europe Hemoglobinopathy Testing Services Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific Hemoglobinopathy Testing Services Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific Hemoglobinopathy Testing Services Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America Hemoglobinopathy Testing Services Sales Value (2021-2032) & (US$ Million) Figure 30. South America Hemoglobinopathy Testing Services Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa Hemoglobinopathy Testing Services Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa Hemoglobinopathy Testing Services Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Hydroxyurea
  • Zynteglo
  • Luspatercept
  • Glutamine
  • Others
Applications
  • Sickle Cell Diseases
  • Thalassemia
  • Other
Companies covered
  • Novartis
  • Eli Lilly and Company
  • Bristol-Myers Squibb
  • AstraZeneca
  • HemaQuest Pharmaceuticals
  • Emmaus Medical
  • Celgene Corporation
  • Bluebird Bio
  • Acceleron Pharma

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Hemoglobinopathy Testing Services Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Hemoglobinopathy Testing Services Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Hemoglobinopathy Testing Services Market Dynamics
  1. 2.1 Hemoglobinopathy Testing Services Industry Trends
  2. 2.2 Hemoglobinopathy Testing Services Industry Drivers
  3. 2.3 Hemoglobinopathy Testing Services Industry Opportunities and Challenges
  4. 2.4 Hemoglobinopathy Testing Services Industry Restraints
3 Hemoglobinopathy Testing Services Market by Company
  1. 3.1 Global Hemoglobinopathy Testing Services Company Revenue Ranking in 2025
  2. 3.2 Global Hemoglobinopathy Testing Services Revenue by Company (2021-2026)
  3. 3.3 Global Hemoglobinopathy Testing Services Company Ranking (2024-2026)
  4. 3.4 Global Hemoglobinopathy Testing Services Company Manufacturing Base and Headquarters
  5. 3.5 Global Hemoglobinopathy Testing Services Company Product Type and Application
  6. 3.6 Global Hemoglobinopathy Testing Services Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Hemoglobinopathy Testing Services Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Hemoglobinopathy Testing Services Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Hemoglobinopathy Testing Services Market by Type
  1. 4.1 Hemoglobinopathy Testing Services Type Introduction
  2. 4.1.1 Hydroxyurea
  3. 4.1.2 Zynteglo
  4. 4.1.3 Luspatercept
  5. 4.1.4 Glutamine
  6. 4.1.5 Others
  7. 4.2 Global Hemoglobinopathy Testing Services Sales Value by Type
  8. 4.2.1 Global Hemoglobinopathy Testing Services Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Hemoglobinopathy Testing Services Sales Value by Type (2021-2032)
  10. 4.2.3 Global Hemoglobinopathy Testing Services Sales Value Share by Type (2021-2032)
5 Hemoglobinopathy Testing Services Market by Application
  1. 5.1 Hemoglobinopathy Testing Services Application Introduction
  2. 5.1.1 Sickle Cell Diseases
  3. 5.1.2 Thalassemia
  4. 5.1.3 Other
  5. 5.2 Global Hemoglobinopathy Testing Services Sales Value by Application
  6. 5.2.1 Global Hemoglobinopathy Testing Services Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hemoglobinopathy Testing Services Sales Value by Application (2021-2032)
  8. 5.2.3 Global Hemoglobinopathy Testing Services Sales Value Share by Application (2021-2032)
6 Hemoglobinopathy Testing Services Regional Value Analysis
  1. 6.1 Global Hemoglobinopathy Testing Services Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hemoglobinopathy Testing Services Sales Value by Region (2021-2032)
  3. 6.2.1 Global Hemoglobinopathy Testing Services Sales Value by Region: 2021-2026
  4. 6.2.2 Global Hemoglobinopathy Testing Services Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Hemoglobinopathy Testing Services Sales Value (2021-2032)
  7. 6.3.2 North America Hemoglobinopathy Testing Services Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Hemoglobinopathy Testing Services Sales Value (2021-2032)
  10. 6.4.2 Europe Hemoglobinopathy Testing Services Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Hemoglobinopathy Testing Services Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Hemoglobinopathy Testing Services Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Hemoglobinopathy Testing Services Sales Value (2021-2032)
  16. 6.6.2 South America Hemoglobinopathy Testing Services Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Hemoglobinopathy Testing Services Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Hemoglobinopathy Testing Services Sales Value Share by Country, 2025 VS 2032
7 Hemoglobinopathy Testing Services Country-level Value Analysis
  1. 7.1 Global Hemoglobinopathy Testing Services Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hemoglobinopathy Testing Services Sales Value by Country (2021-2032)
  3. 7.2.1 Global Hemoglobinopathy Testing Services Sales Value by Country (2021-2026)
  4. 7.2.2 Global Hemoglobinopathy Testing Services Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Hemoglobinopathy Testing Services Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Hemoglobinopathy Testing Services Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Hemoglobinopathy Testing Services Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Novartis
  2. 8.1.1 Novartis Company Information
  3. 8.1.2 Novartis Business Overview
  4. 8.1.3 Novartis Hemoglobinopathy Testing Services Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Novartis Hemoglobinopathy Testing Services Product Portfolio
  6. 8.1.5 Novartis Recent Developments
  7. 8.2 Eli Lilly and Company
  8. 8.2.1 Eli Lilly and Company Company Information
  9. 8.2.2 Eli Lilly and Company Business Overview
  10. 8.2.3 Eli Lilly and Company Hemoglobinopathy Testing Services Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Eli Lilly and Company Hemoglobinopathy Testing Services Product Portfolio
  12. 8.2.5 Eli Lilly and Company Recent Developments
  13. 8.3 Bristol-Myers Squibb
  14. 8.3.1 Bristol-Myers Squibb Company Information
  15. 8.3.2 Bristol-Myers Squibb Business Overview
  16. 8.3.3 Bristol-Myers Squibb Hemoglobinopathy Testing Services Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Bristol-Myers Squibb Hemoglobinopathy Testing Services Product Portfolio
  18. 8.3.5 Bristol-Myers Squibb Recent Developments
  19. 8.4 AstraZeneca
  20. 8.4.1 AstraZeneca Company Information
  21. 8.4.2 AstraZeneca Business Overview
  22. 8.4.3 AstraZeneca Hemoglobinopathy Testing Services Revenue and Gross Margin (2021-2026)
  23. 8.4.4 AstraZeneca Hemoglobinopathy Testing Services Product Portfolio
  24. 8.4.5 AstraZeneca Recent Developments
  25. 8.5 HemaQuest Pharmaceuticals
  26. 8.5.1 HemaQuest Pharmaceuticals Company Information
  27. 8.5.2 HemaQuest Pharmaceuticals Business Overview
  28. 8.5.3 HemaQuest Pharmaceuticals Hemoglobinopathy Testing Services Revenue and Gross Margin (2021-2026)
  29. 8.5.4 HemaQuest Pharmaceuticals Hemoglobinopathy Testing Services Product Portfolio
  30. 8.5.5 HemaQuest Pharmaceuticals Recent Developments
  31. 8.6 Emmaus Medical
  32. 8.6.1 Emmaus Medical Company Information
  33. 8.6.2 Emmaus Medical Business Overview
  34. 8.6.3 Emmaus Medical Hemoglobinopathy Testing Services Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Emmaus Medical Hemoglobinopathy Testing Services Product Portfolio
  36. 8.6.5 Emmaus Medical Recent Developments
  37. 8.7 Celgene Corporation
  38. 8.7.1 Celgene Corporation Company Information
  39. 8.7.2 Celgene Corporation Business Overview
  40. 8.7.3 Celgene Corporation Hemoglobinopathy Testing Services Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Celgene Corporation Hemoglobinopathy Testing Services Product Portfolio
  42. 8.7.5 Celgene Corporation Recent Developments
  43. 8.8 Bluebird Bio
  44. 8.8.1 Bluebird Bio Company Information
  45. 8.8.2 Bluebird Bio Business Overview
  46. 8.8.3 Bluebird Bio Hemoglobinopathy Testing Services Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Bluebird Bio Hemoglobinopathy Testing Services Product Portfolio
  48. 8.8.5 Bluebird Bio Recent Developments
  49. 8.9 Acceleron Pharma
  50. 8.9.1 Acceleron Pharma Company Information
  51. 8.9.2 Acceleron Pharma Business Overview
  52. 8.9.3 Acceleron Pharma Hemoglobinopathy Testing Services Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Acceleron Pharma Hemoglobinopathy Testing Services Product Portfolio
  54. 8.9.5 Acceleron Pharma Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst